KALA-AZAR ASSOCIATED WITH COOMBS-POSITIVE AUTOIMMUNE HEMOLYTIC ANEMIA IN THE PATIENTS COMING FROM THE ENDEMIC AREA OF THIS DISEASE AND SUCCESSFUL TREATMENT OF THESE PATIENTS WITH LIPOSOMAL AMPHOTERICIN B

2005 ◽  
Vol 22 (5) ◽  
pp. 349-355 ◽  
Author(s):  
Erol Erduran ◽  
Aysenur Bahadir ◽  
Yusuf Gedik
Keyword(s):  
Amphotericin B ◽  
Hemolytic Anemia ◽  
Successful Treatment ◽  
Autoimmune Hemolytic Anemia ◽  
Liposomal Amphotericin ◽  
Endemic Area ◽  
Liposomal Amphotericin B ◽  
Kala Azar

Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis

2019 ◽  
Vol 221 (4) ◽  
pp. 608-617 ◽  
Author(s):  
V Ramesh ◽  
Keerti Kaumudee Dixit ◽  
Neha Sharma ◽  
Ruchi Singh ◽  
Poonam Salotra
Keyword(s):  
Combination Therapy ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Quantitative Polymerase Chain Reaction ◽  
Treatment Options ◽  
Parasite Load ◽  
Liposomal Amphotericin B ◽  
Rapid Decline ◽  
Kala Azar

Abstract Background No satisfactory canonical treatment is available for post-kala-azar dermal leishmaniasis (PKDL), clinical sequela of visceral leishmaniasis. Confined treatment options and substantial increase in relapse rate after miltefosine (MIL) treatment warrant the need to adapt resilient combination therapies. In this study, we assessed the safety and efficacy of combination therapy using liposomal amphotericin B (LAmB) and MIL for treating PKDL. Methods Thirty-two PKDL patients, confirmed by microscopy or quantitative polymerase chain reaction (qPCR), were included in the study. An equal number of cases (n = 16) were put on MIL monotherapy (100 mg/day for 90 days) or MIL and LAmB combination for 45 days (3 injections of LAmB, 5 mg/kg body weight, and 100 mg/day MIL). Parasite load in slit aspirate was monitored using qPCR. Results Patients treated with combination therapy demonstrated a rapid decline in parasite load and achieved 100% cure, with no reports of relapse. Those treated with MIL monotherapy attained clinical cure with a gradual decrease in parasite load; however, 25% relapsed within 18 months of follow-up. Conclusions Liposomal amphotericin B and MIL combination for treating PKDL is efficacious and safe, with high tolerability. Furthermore, this study established the utility of minimally invasive slit aspirate method for monitoring of parasite load and assessment of cure in PKDL.

Successful treatment of focal hepatic candidiasis with liposomal amphotericin B

1992 ◽  
Vol 161 (12) ◽  
pp. 664-665 ◽  
Author(s):  
B. O’Connell ◽  
G. Crotty ◽  
M. T. Cafferkey ◽  
R. Stephens ◽  
G. S. A. McDonald ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Successful Treatment ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B

Treatment experience with liposomal amphotericin B in pediatric patients with kala-azar

2015 ◽  
Vol 4 (3) ◽  
pp. 222-229
Author(s):  
Can Acıpayam ◽  
Gülnaz Çulha ◽  
Ali Altunay ◽  
Fazilet Akoğlu ◽  
Alkan Yeral ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Pediatric Patients ◽  
Liposomal Amphotericin B ◽  
Treatment Experience ◽  
Kala Azar
Sign in / Sign up

Export Citation Format

Share Document